Sartorius Aktiengesellschaft (SSSGY)
USD 39.0
(0.0%)
USD 39.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.02 Billion EUR | 0.35% |
| 2022 | 1.02 Billion EUR | 12.67% |
| 2021 | 905.59 Million EUR | 30.29% |
| 2020 | 695.07 Million EUR | 20.33% |
| 2019 | 577.65 Million EUR | 14.85% |
| 2018 | 502.98 Million EUR | 13.31% |
| 2017 | 443.88 Million EUR | 15.56% |
| 2016 | 384.12 Million EUR | 12.95% |
| 2015 | 340.09 Million EUR | 13.57% |
| 2014 | 299.47 Million EUR | -1.93% |
| 2013 | 305.36 Million EUR | 3.68% |
| 2012 | 294.52 Million EUR | 11.44% |
| 2011 | 264.29 Million EUR | 10.55% |
| 2010 | 239.07 Million EUR | -3.75% |
| 2009 | 248.39 Million EUR | 8.23% |
| 2008 | 229.51 Million EUR | 2.76% |
| 2007 | 223.34 Million EUR | 16.62% |
| 2006 | 191.52 Million EUR | 4.95% |
| 2005 | 182.49 Million EUR | -0.43% |
| 2004 | 183.28 Million EUR | -3.18% |
| 2003 | 189.31 Million EUR | -2.8% |
| 2002 | 194.77 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 240.3 Million EUR | -4.79% |
| 2024 Q1 | 273.8 Million EUR | 46.92% |
| 2024 Q3 | 276.9 Million EUR | 15.23% |
| 2023 Q3 | 279.9 Million EUR | -0.57% |
| 2023 Q4 | 171.8 Million EUR | -38.62% |
| 2023 FY | 1.02 Billion EUR | 0.35% |
| 2023 Q1 | 290.8 Million EUR | 32.6% |
| 2023 Q2 | 281.5 Million EUR | -3.2% |
| 2022 Q4 | 219.3 Million EUR | -22.7% |
| 2022 Q3 | 283.7 Million EUR | 10.13% |
| 2022 FY | 1.02 Billion EUR | 12.67% |
| 2022 Q2 | 257.6 Million EUR | -0.73% |
| 2022 Q1 | 259.5 Million EUR | 18.12% |
| 2021 Q1 | 211.9 Million EUR | 42.05% |
| 2021 FY | 905.59 Million EUR | 30.29% |
| 2021 Q4 | 219.69 Million EUR | -11.74% |
| 2021 Q2 | 225.1 Million EUR | 6.23% |
| 2021 Q3 | 248.9 Million EUR | 10.57% |
| 2020 Q1 | 174.7 Million EUR | 16.97% |
| 2020 FY | 695.07 Million EUR | 20.33% |
| 2020 Q4 | 149.17 Million EUR | -19.5% |
| 2020 Q3 | 185.3 Million EUR | 0.05% |
| 2020 Q2 | 185.2 Million EUR | 6.01% |
| 2019 Q4 | 149.35 Million EUR | -3.08% |
| 2019 Q2 | 149.1 Million EUR | 3.9% |
| 2019 Q1 | 143.5 Million EUR | 16.87% |
| 2019 Q3 | 154.1 Million EUR | 3.35% |
| 2019 FY | 577.65 Million EUR | 14.85% |
| 2018 Q2 | 133.9 Million EUR | 0.98% |
| 2018 FY | 502.98 Million EUR | 13.31% |
| 2018 Q4 | 122.78 Million EUR | -7.4% |
| 2018 Q3 | 132.6 Million EUR | -0.97% |
| 2018 Q1 | 132.6 Million EUR | 49.35% |
| 2017 Q1 | 113.9 Million EUR | 42.15% |
| 2017 FY | 443.88 Million EUR | 15.56% |
| 2017 Q4 | 88.78 Million EUR | -27.17% |
| 2017 Q3 | 121.9 Million EUR | 2.18% |
| 2017 Q2 | 119.3 Million EUR | 4.74% |
| 2016 Q3 | 108.8 Million EUR | 12.98% |
| 2016 Q2 | 96.3 Million EUR | -2.63% |
| 2016 Q1 | 98.9 Million EUR | 46.1% |
| 2016 FY | 384.12 Million EUR | 12.95% |
| 2016 Q4 | 80.12 Million EUR | -26.35% |
| 2015 Q2 | 93.2 Million EUR | 11.62% |
| 2015 Q1 | 83.5 Million EUR | 70.86% |
| 2015 FY | 340.09 Million EUR | 13.57% |
| 2015 Q3 | 95.7 Million EUR | 2.68% |
| 2015 Q4 | 67.69 Million EUR | -29.26% |
| 2014 Q2 | 84.4 Million EUR | 3.56% |
| 2014 FY | 299.47 Million EUR | -1.93% |
| 2014 Q4 | 48.87 Million EUR | -42.23% |
| 2014 Q3 | 84.6 Million EUR | 0.24% |
| 2014 Q1 | 81.5 Million EUR | 17.83% |
| 2013 Q2 | 81.8 Million EUR | 6.1% |
| 2013 Q3 | 77.4 Million EUR | -5.38% |
| 2013 FY | 305.36 Million EUR | 3.68% |
| 2013 Q4 | 69.16 Million EUR | -10.64% |
| 2013 Q1 | 77.1 Million EUR | 26.35% |
| 2012 Q3 | 77.1 Million EUR | -1.78% |
| 2012 FY | 294.52 Million EUR | 11.44% |
| 2012 Q1 | 77.8 Million EUR | 17.54% |
| 2012 Q2 | 78.5 Million EUR | 0.9% |
| 2012 Q4 | 61.02 Million EUR | -20.85% |
| 2011 Q2 | 71.6 Million EUR | 14.38% |
| 2011 Q3 | 63.8 Million EUR | -10.89% |
| 2011 Q4 | 66.19 Million EUR | 3.75% |
| 2011 Q1 | 62.6 Million EUR | 4.03% |
| 2011 FY | 264.29 Million EUR | 10.55% |
| 2010 Q2 | 61.9 Million EUR | 8.41% |
| 2010 FY | 239.07 Million EUR | -3.75% |
| 2010 Q4 | 60.17 Million EUR | -0.38% |
| 2010 Q3 | 60.4 Million EUR | -2.42% |
| 2010 Q1 | 57.1 Million EUR | -1.55% |
| 2009 Q3 | 58.4 Million EUR | -21.29% |
| 2009 FY | 248.39 Million EUR | 8.23% |
| 2009 Q1 | 57.7 Million EUR | 0.0% |
| 2009 Q2 | 74.2 Million EUR | 28.6% |
| 2009 Q4 | 57.99 Million EUR | -0.69% |
| 2008 FY | 229.51 Million EUR | 2.76% |
| 2007 FY | 223.34 Million EUR | 16.62% |
| 2006 FY | 191.52 Million EUR | 4.95% |
| 2005 FY | 182.49 Million EUR | -0.43% |
| 2004 FY | 183.28 Million EUR | -3.18% |
| 2003 FY | 189.31 Million EUR | -2.8% |
| 2002 FY | 194.77 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Medical Technologies Inc. | 2.86 Million USD | -35659.101% |
| Ansell Limited | 495.5 Million USD | -106.64% |
| Ansell Limited | 495.5 Million USD | -106.64% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 82.8 Million USD | -1136.538% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 1.73 Million USD | -59059.119% |
| Psykey, Inc. | 1.21 Million USD | -84277.163% |
| ConvaTec Group Plc | 910.31 Million USD | -12.477% |
| ConvaTec Group Plc | 872.5 Million USD | -17.352% |
| Encision Inc. | 3.77 Million USD | -27010.647% |
| Golden Valley Development, Inc | 141.81 Thousand USD | -721917.333% |
| Hear AtLast Holdings, Inc. | 109.93 Thousand USD | -931302.425% |
| Innovative MedTech Inc. | 6.09 Million USD | -16687.995% |
| LifePoint, Inc. | 7.42 Million USD | -13691.998% |
| Medite Cancer Diagnostics, Inc. | 6.34 Million USD | -16026.949% |
| Paradigm Medical Industries, Inc. | 855 Thousand USD | -119654.386% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 726.13 Thousand USD | -140907.032% |
| Reflect Scientific, Inc. | 1.06 Million USD | -96158.434% |
| SmileDirectClub, Inc. | 517 Million USD | -98.045% |
| Sector 10, Inc. | 39.84 Thousand USD | -2569672.111% |
| Shandong Weigao Group Medical Polymer Company Limited | 6.64 Billion USD | 84.587% |
| SheerVision, Inc. | 2.33 Million USD | -43813.391% |
| United Health Products, Inc. | 2.42 Million USD | -42095.901% |
| Vasamed, Inc. | 4.67 Million USD | -21811.381% |
| Wearable Health Solutions, Inc. | 2.56 Million USD | -39867.929% |
| Yubo International Biotech Limited | 1.25 Million USD | -81299.185% |